Renaissance Technologies
SCLN

Renaissance Technologies’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Renaissance Technologies’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,540,200
Closed -$27.9M – 3506
2017
Q2 		$27.9M Buy
2,540,200
+456,100
+22% +$4.56M 0.04% 655
2017
Q1 		$20.4M Buy
2,084,100
+314,202
+18% +$3.14M 0.03% 786
2016
Q4 		$19.1M Buy
1,769,898
+384,898
+28% +$3.85M 0.03% 822
2016
Q3 		$14.2M Buy
1,385,000
+223,300
+19% +$2.43M 0.03% 937
2016
Q2 		$15.2M Buy
1,161,700
+229,400
+25% +$3.01M 0.03% 872
2016
Q1 		$10.3M Buy
932,300
+349,220
+60% +$3.11M 0.02% 1122
2015
Q4 		$5.36M Buy
583,080
+139,580
+31% +$1.17M 0.01% 1425
2015
Q3 		$3.08M Sell
443,500
-248,160
-36% -$2.13M 0.01% 1712
2015
Q2 		$6.79M Buy
691,660
+251,260
+57% +$2.29M 0.02% 1220
2015
Q1 		$3.9M Buy
440,400
+240,980
+121% +$1.92M 0.01% 1519
2014
Q4 		$1.75M Buy
199,420
+113,520
+132% +$919K ﹤0.01% 1877
2014
Q3 		$592K Sell
85,900
-235,426
-73% -$1.41M ﹤0.01% 2253
2014
Q2 		$1.69M Buy
321,326
+58,319
+22% +$284K ﹤0.01% 1811
2014
Q1 		$1.2M Buy
263,007
+28,103
+12% +$136K ﹤0.01% 2000
2013
Q4 		$1.18M Sell
234,904
-271,196
-54% -$1.31M ﹤0.01% 1994
2013
Q3 		$2.57M Buy
506,100
+370,300
+273% +$2.06M 0.01% 1538
2013
Q2 		$674K Buy
+135,800
New +$646K ﹤0.01% 2109

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Renaissance Technologies's SCLN Position: Q3 2017 in Review

Renaissance Technologies sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q3 2017, closing a stake of 2,540,200 shares — an estimated $27.9M sold.

Renaissance Technologies first reported a position in SCLN in Q2 2013 and held it in 17 quarters. The position peaked at $27.9M in Q2 2017. 129 funds tracked by Wall St. Rank hold SCLN as of Q3 2017.

  • Renaissance Technologies reported no remaining Sciclone Pharmaceuticals Inc position as of Q3 2017 after selling out during the quarter.
  • Renaissance Technologies sold 2,540,200 Sciclone Pharmaceuticals Inc shares in Q3 2017, an estimated $27.9M.
  • Renaissance Technologies first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 17 quarters.
  • Renaissance Technologies's Sciclone Pharmaceuticals Inc position peaked at $27.9M in Q2 2017.
  • 129 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q3 2017.

Based on Renaissance Technologies's 13F filing for Q3 2017, filed 13 Nov 2017.